

# Alessandro Tomelleri

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5000339/alessandro-tomelleri-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75  
papers

1,589  
citations

14  
h-index

39  
g-index

98  
ext. papers

2,116  
ext. citations

4.7  
avg, IF

5.07  
L-index

#	Paper	IF	Citations
75	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e325-e331	14.2	612
74	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 76, 43-49	3.9	270
73	GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e465-e473	14.2	130
72	Erdheim-Chester disease. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 223-9	3.9	99
71	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e253-e261	14.2	75
70	Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1252-1253	2.4	40
69	FRI0506 EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILL'S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 851.1-852	2.4	33
68	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1233	8.4	32
67	Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 54	5.7	25
66	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 57, e11-e12	3.9	24
65	Tocilizumab in patients with multisystem Erdheim-Chester disease. <i>Oncolmmunology</i> , <b>2017</b> , 6, e1318237.2	7.2	23
64	Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	20
63	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 675678	8.4	18
62	Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , <b>2020</b> , 59, 171-175	3.9	17
61	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 598308	5.6	14
60	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>Oncolmmunology</i> , <b>2018</b> , 7, e1440929	7.2	13
59	Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , <b>2019</b> , 48, 482-490	1.9	12

58	Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. <i>International Journal of Cardiology</i> , <b>2018</b> , 252, 21-23	3.2	12
57	Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	12
56	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 27, e143-e146	1.1	10
55	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 509-514	5.3	9
54	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> ,	2.4	9
53	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 653950	8.4	7
52	Response to: 'Correspondence on 'Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey' by Comarmond. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	6
51	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 1-6	5.3	6
50	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 93, 87-94	3.9	6
49	Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	5
48	Efficacy and safety of TNF- $\alpha$ antagonists and tocilizumab in Takayasu arteritis: Multicenter retrospective study of 209 patients. <i>Rheumatology</i> , <b>2021</b> ,	3.9	5
47	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. <i>Rheumatology</i> , <b>2021</b> , 60, 4361-4366	3.9	4
46	Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e248-e249	14.2	4
45	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use. <i>Journal of Clinical Rheumatology</i> , <b>2019</b> ,	1.1	4
44	Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. <i>Rheumatology</i> , <b>2021</b> , 60, 465-467	3.9	3
43	Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.. <i>Cell Reports Medicine</i> , <b>2022</b> , 3, 100560	18	3
42	AB0466 EFFICACY AND SAFETY OF INFLIXIMAB-BIOSIMILAR IN TAKAYASU ARTERITIS (TAKASIM): A MONOCENTRIC, OBSERVATIONAL, PROSPECTIVE, OPEN-LABEL STUDY. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1531.2-1531	2.4	2
41	Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study. <i>Scandinavian Journal of Rheumatology</i> , <b>2021</b> , 1-8	1.9	2

40	Current and innovative therapeutic strategies for the treatment of giant cell arteritis. <i>Expert Opinion on Orphan Drugs</i> , <b>2021</b> , 9, 161-173	1.1	2
39	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , <b>2021</b> , 138, 1554-1569	2.2	2
38	AB0621 GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS <b>2019</b> ,		2
37	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 129-134	2.2	2
36	Multimodal Chorioretinal Imaging in Erdheim-Chester Disease. <i>Clinical Ophthalmology</i> , <b>2020</b> , 14, 581-588.	5	1
35	Clinically isolated aortitis successfully treated with methotrexate monotherapy. <i>Rheumatology</i> , <b>2020</b> , 59, e54-e56	3.9	1
34	An enlightening scan. <i>European Journal of Internal Medicine</i> , <b>2015</b> , 26, 68-9	3.9	1
33	Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. <i>Lancet Rheumatology</i> , <b>2021</b> ,	14.2	1
32	POS0337 SOUTHEND PRE-TEST PROBABILITY SCORE AND HALO SCORE AS MARKERS FOR DIAGNOSIS AND MONITORING OF GCA: EARLY RESULTS FROM THE PROSPECTIVE HAS-GCA STUDY. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 396-397	2.4	1
31	Long-Term Efficacy and Safety of Leflunomide in Large-Vessel Giant Cell Arteritis: A Single-Center, 10-Year Experience. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> ,	1.1	1
30	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 129, 129-134	2.2	1
29	Successful use of cyclosporin A and interleukin-1 blockers combination in VEXAS syndrome: a single-centre case series.. <i>Arthritis and Rheumatology</i> , <b>2022</b> ,	9.5	1
28	Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data.. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 55, 152017	5.3	1
27	AB0631 Hypersensitivity to Rituximab: A Rapid and Simplified Desensitization Protocol for Patients with Anca-Associated Vasculitis and Other Autoimmune Disorders. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1110.1-1110	2.4	0
26	FRI0478 SEROLOGICAL AUTOIMMUNITY IN PATIENTS WITH RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS: CORRELATION WITH SEVERITY AND TREATMENT. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 836.2-836	2.4	0
25	Myocarditis as a manifestation of Erdheim-Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy. <i>Scandinavian Journal of Rheumatology</i> , <b>2021</b> , 1-3	1.9	0
24	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1780-1784	4.1	0
23	Spontaneous Coronary-Artery Dissection. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1077	59.2	0

22	AB0361 EFFECTIVENESS AND SAFETY OF INFLIXIMAB DOSE ESCALATION IN PATIENTS WITH REFRACTORY TAKAYASU ARTERITIS: A REAL-LIFE EXPERIENCE FROM A MONOCENTRIC COHORT. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1206.1-1206	2.4	○
21	POS1341 TOCILIZUMAB FOR THE TREATMENT OF IMMUNE-RELATED ADVERSE EVENTS TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 953.1-953.4	2.4	○
20	Bilateral temporal arteries 18F-FDG PET uptake in giant cell arteritis. <i>Rheumatology</i> , <b>2020</b> , 59, 343	3.9	○
19	Canakinumab injection for the treatment of active Still's disease, including adult-onset Still's disease. <i>Expert Opinion on Orphan Drugs</i> , <b>2021</b> , 9, 77-86	1.1	○
18	Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement. <i>International Journal of Dermatology</i> , <b>2021</b> , 60, e359-e361	1.7	○
17	A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 723506	4.9	○
16	Looking ahead: giant-cell arteritis in 10 years time. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X2210963	3.8	○
15	THU0363 Pilot Study of TOCILIZUMAB in Patients with Erdheim-Chester Disease. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 308.1-308	2.4	
14	THU0372 The Role of Echocardiography and Cardiac MRI in Erdheim-Chester Disease. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 311.1-311	2.4	
13	Comment on: Diagnostic accuracy of ultrasound for detecting large-vessel giant cell arteritis using FDG PET/CT as the reference. <i>Rheumatology</i> , <b>2021</b> , 60, e66	3.9	
12	FRI0191 CRANIAL-LIMITED AND LARGE-VESSEL GIANT CELL ARTERITIS: PRESENTING FEATURES AND OUTCOME. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 678.3-679	2.4	
11	FRI0212 THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 689.1-690	2.4	
10	FRI0484 SAFETY PROFILE, CLINICAL AND RADIOLOGICAL EFFICACY OF ANAKINRA, TARGETED AND COMBINED TREATMENT IN ERDHEIM-CHESTER DISEASE. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 839.1-840	2.4	
9	FRI0214 PERSISTENT LOW-GRADE FDG-PET VASCULAR INFLAMMATION IN REMITTED LVV-GCA PATIENTS IS ASSOCIATED TO A SIGNIFICANT HIGH RISK OF RELAPSE. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 690.2-691	2.4	
8	AB0534 EFFICACY OF TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS: A SINGLE-CENTER REAL-LIFE EXPERIENCE. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1563.1-1564	2.4	
7	SAT0519 DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1215-1216	2.4	
6	THU0298 SWITCH OR SWAP STRATEGY IN TAKAYASU ARTERITIS PATIENTS FAILING TNFA INHIBITORS?. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 377-377	2.4	
5	POS1347 IMPACT OF CANAKINUMAB AND ANAKINRA ON PATIENT-REPORTED OUTCOMES IN ADULT-ONSET STILL'S DISEASE PATIENTS. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 955.3-956	2.4	

- 4 POS1336 RETROPERITONEAL FIBROSIS IN ERDHEIM-CHESTER DISEASE HAS UNIQUE PRESENTING AND PROGNOSTIC FEATURES: A SINGLE CENTRE RETROSPECTIVE COMPARATIVE COHORT STUDY. *Annals of the Rheumatic Diseases*, **2021**, 80, 950-951 2.4
- 3 POS0806 FINDINGS CONSISTENT WITH SUBCLINICAL VASCULITIS IN PATIENTS WITH NEW ONSET POLYMYALGIA: A SYSTEMATIC LITERATURE REVIEW AND A META-ANALYSIS OF COHORT DATA. *Annals of the Rheumatic Diseases*, **2021**, 80, 655.2-656 2.4
- 2 Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. *Journal of Scleroderma and Related Disorders*, 239719832210837 2.3
- 1 Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. *Clinical and Experimental Rheumatology*, **2022**, 2.2